Search

How to apply for an EHA Kick-off Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.

Read more

How to apply for an EHA Bilateral Collaborative Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Bilateral Collaborative Grant application.

Read more

Registration & accommodation

Registration is now closed

Individual registrationHybrid registration includes:

In-person access to the scientific and educational sessions of the meeting
Access to the virtual platform
Meeting materials
Coffee/tea breaks on February 9-11, 2023 and lunches on February 10 & 11
Access to the Welcome Reception
Access to the…

Read more

Patient Advocacy Committee

Current committee members
Derek Elston, United Kingdom (Chair)
Samantha Nier, Switzerland (Vice-chair)
Loris Brunetta, Italy (Vice-chair)
Members representing a Patient Advocacy Organization

Organization
Member

Acute Leukaemia Advocates Network (ALAN)

Samantha Nier

CCI Europe

Anita Kienesberger

CLL Advocates Network (CLLAN)

Pierre Aumont

CML Advocates Network

Jan Geissler

European Federation of Associations of Patients with Haemochromatosis (EFAPH)

Dag…

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

Full membership

Our most popular type of membership is designed for established scientific researchers and physicians.

Read more

The glamorous life of parenthood and medicine

The glamorous life of parenthood and medicine

By Ana Zelić Kerep, MD (YoungEHA Ambassador)

Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more